Zydus Lifesciences Q4 Revenue Up 16% YoY

Zydus Lifesciences reported Q4 FY26 revenue of ₹75,870 mn, a 16% YoY growth, with EBITDA margin expanding 110 bps to 33.7%.
The India branded formulations business grew 15% YoY, outperforming the market, while North America saw sequential growth from new launches.
The company announced a ₹11,000 mn share buyback at ₹1,150 per share and acquired US-based Assertio Holdings for $166 mn.
R&D expenditure stood at ₹6,982 mn (9.2% of revenue), with key biosimilar launches including Tishtha (Nivolumab) and Anyra (Aflibercept).